Phibro Animal Health Corporatio (PAHC) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.79
- Estimate
- $0.78
- Surprise
- +0.9%
- Revenue (period 2026-09-30)
- $386.8M
- Score at report (before → after)
- 5.7 → 5.8/10
Revenue source: xbrl.
How the report landed
Phibro Animal Health Corporatio (PAHC) beat the $0.78 estimate with adjusted EPS of $0.79 — a modest 0.9% upside surprise. TrendMatrix's engine moved from Sell (5.7/10) to Hold at 5.8/10 after the report.
Coverage in the report window
- Phibro Animal Health Q1 2027 Earnings Call Transcript — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates PAHC Hold at 5.8/10.
4 of the last 4 quarters beat the estimate; this quarter's +0.9% surprise compares with a +13.6% four-quarter average. Next scheduled report: 2027-02-03.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Product: livestock sector
- V7 low-quality RISK_OFF penalty: -0.5 (Q=5.4)
- Leverage penalty (D/E 2.1): -1.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $34.15
- Price target
- $39.95
- Stop
- $32.79
- Upside to target
- +17.0%
- Reward-to-risk
- 1.7:1
The stock trades at 14.1× trailing but 9.2× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
PAHC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.44B
- P/E (fwd)
- 9.2
- P/E (ttm)
- 14.1
- 52-week range
- $28.25–$60.08
- Off 52-week high
- 43.2%
- RSI (14)
- 30
- Volume vs avg
- 0.36×
- Score today
- 5.8/10